GBM can undergo senescence following radiation or temozolomide treatment and preclinical studies have shown that targeting senescent cells through Bcl-xL inhibition could be a valuable therapeutic strategy for improving GBM treatment outcomes2,5,23,48. This evidence concerns the gene BCL2L1 and glioblastoma.